Intervention strategies for an influenza pandemic taking into account secondary bacterial infections

Epidemics

Volumn 1, Issue 3, 2009, Pages 185-195

  Handel, Andreas ^a   Longini Jr , Ira M ^c   Antia, Rustom ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antiviral and antibacterial treatment and prophylaxis; Co infection; Epidemic control; Influenza pandemic; Mathematical model

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT;

ARTICLE; BACTERIAL INFECTION; DISEASE SEVERITY; DISEASE TRANSMISSION; HUMAN; INFECTION CONTROL; INFLUENZA; MORBIDITY; MORTALITY; PANDEMIC; PRIORITY JOURNAL; VIRUS STRAIN;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; ORTHOMYXOVIRIDAE; PANDEMICS; UNITED STATES;

EID: 70350752187     PISSN: 17554365     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.epidem.2009.09.001     Document Type: Article

References (96)

1. Oseltamivir-resistant novel influenza a (h1n1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR 58 (2009) 893-896
2. Alexander M.E., Bowman C.S., Feng Z., Gardam M., Moghadas S.M., Röst G., Wu J., and Yan P. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc. Biol. Sci. 274 1619 (2007) 1675-1684. http://dx.doi.org/10.1098/rspb.2007.0422 URL http://dx.doi.org/10.1098/rspb.2007.0422. Jul
3. Anderson R.M., and May R.M. Infectious Diseases of Humans - Dynamics and Control (1991), Oxford Science Publications, Oxford
4. Aoki F.Y., Macleod M.D., Paggiaro P., Carewicz O., Sawy A.E., Wat C., Griffiths M., Waalberg E., Ward P., and Group I.M.P.A.C.T.S. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51 1 (2003) 123-129 Jan
5. Bassetti S., Bischoff W.E., Walter M., Bassetti-Wyss B.A., Mason L., Reboussin B.A., D'Agostino R.B., Gwaltney J.M., Pfaller M.A., and Sherertz R.J. Dispersal of staphylococcus aureus into the air associated with a rhinovirus infection. Infect. Control. Hosp. Epidemiol. 26 2 (2005) 196-203 Feb
6. Bhat N., Wright J.G., Broder K.R., Murray E.L., Greenberg M.E., Glover M.J., Likos A.M., Posey D.L., Klimov A., Lindstrom S.E., Balish A., jo Medina M., Wallis T.R., Guarner J., Paddock C.D., Shieh W.-J., Zaki S.R., Sejvar J.J., Shay D.K., Harper S.A., Cox N.J., Fukuda K., Uyeki T.M., and Team I.S.I. Influenza-associated deaths among children in the united states, 2003-2004. N. Engl. J. Med. 353 24 (2005) 2559-2567 Dec
7. Blower S.M., and Dowlatabadi H. Sensitivity and uncertainty analysis of complex-models of disease transmission-an HIV model, as an example. Int. Sta. Rev. 62 2 (1994) 229-243 Aug
8. Bonten M.J.M., and Prins J.M. Antibiotics in pandemic flu. BMJ 332 7536 (2006) 248-249. http://dx.doi.org/10.1136/bmj.332.7536.248 URL http://dx.doi.org/10.1136/bmj.332.7536.248. Feb
9. Brimblecombe F.S., Cruickshank R., Masters P.L., Reid D.D., and Stewart G.T. Family studies of respiratory infections. Br. Med. J. 1 5063 (1958) 119-128 Jan
10. Brockmann S.O., Schwehm M., Duerr H.-P., Witschi M., Koch D., Vidondo B., and Eichner M. Modeling the effects of drug resistant influenza virus in a pandemic. Virol. J. 5 (2008) 133. http://dx.doi.org/10.1186/1743-422X-5-133 URL http://dx.doi.org/10.1186/1743-422X-5-133
11. Brundage J.F. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect. Dis. 6 5 (2006) 303-312. http://dx.doi.org/10.1016/S1473-3099 URL http://dx.doi.org/10.1016/S1473-3099(06)70466-2. May
12. Brundage J.F., and Shanks G.D. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg. Infect. Dis. 14 8 (2008) 1193-1199 Aug
13. Carrat F., Schwarzinger M., Housset B., and Valleron A.-J. Antibiotic treatment for influenza does not affect resolution of illness, secondary visits or lost workdays. Eur. J. Epidemiol. 19 7 (2004) 703-705
14. Carrat F., Vergu E., Ferguson N.M., Lemaitre M., Cauchemez S., Leach S., and Valleron A.-J. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am. J. Epidemiol. 167 7 (2008) 775-785. http://dx.doi.org/10.1093/aje/kwm375 URL http://dx.doi.org/10.1093/aje/kwm375. Apr
15. Cartwright K.A., Jones D.M., Smith A.J., Stuart J.M., Kaczmarski E.B., and Palmer S.R. Influenza a and meningococcal disease. Lancet 338 8766 (1991) 554-557 Aug
16. Cole J.A., Loughlin J.E., Ajene A.N., Rosenberg D.M., Cook S.E., and Walker A.M. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin. Ther. 24 11 (2002) 1824-1839 Nov
17. Dancer S.J. How antibiotics can make us sick: the less obvious adverse effects of antimicrobial chemotherapy. Lancet Infect. Dis. 4 (2004) 611-619
18. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 9297 (2001) 1975-1982. http://dx.doi.org/10.1016/S0140-6736 URL http://dx.doi.org/10.1016/S0140-6736(01)06964-1. Dec
19. Eichner M., Schwehm M., Duerr H.-P., Witschi M., Koch D., Brockmann S.O., and Vidondo B. Antiviral prophylaxis during pandemic influenza may increase drug resistance. BMC Infect. Dis. 9 (2009) 4. http://dx.doi.org/10.1186/1471-2334-9-4 URL http://dx.doi.org/10.1186/1471-2334-9-4
20. Ferguson N.M., Cummings D.A.T., Cauchemez S., Fraser C., Riley S., Meeyai A., Iamsirithaworn S., and Burke D.S. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437 7056 (2005) 209-214 Sep
21. Ferguson N.M., Cummings D.A.T., Fraser C., Cajka J.C., Cooley P.C., and Burke D.S. Strategies for mitigating an influenza pandemic. Nature 442 7101 (2006) 448-452. http://dx.doi.org/10.1038/nature04795 URL http://dx.doi.org/10.1038/nature04795. Jul
22. For Disease Control, C., Prevention, 2009. 2009 h1n1 flu. URL http://www.cdc.gov/h1n1flu/.
23. Fraser C., Donnelly C.A., Cauchemez S., Hanage W.P., Kerkhove M.D.V., Hollingsworth T.D., Griffin J., Baggaley R.F., Jenkins H.E., Lyons E.J., Jombart T., Hinsley W.R., Grassly N.C., Balloux F., Ghani A.C., Ferguson N.M., Rambaut A., Pybus O.G., Lopez-Gatell H., Alpuche-Aranda C.M., Chapela I.B., Zavala E.P., Guevara D.M.E., Checchi F., Garcia E., Hugonnet S., Roth C., and Collaboration W.H.O.R.P.A. Pandemic potential of a strain of influenza a (h1n1): early findings. Science 324 5934 (2009) 1557-1561 Jun
24. Garske T., Legrand J., Donnelly C.A., Ward H., Cauchemez S., Fraser C., Ferguson N.M., and Ghani A.C. Assessing the severity of the novel influenza a/h1n1 pandemic. BMJ b2840 (2009) 339
25. Germann T.C., Kadau K., Longini I.M., and Macken C.A. Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. U. S. A. 103 15 (2006) 5935-5940 Apr
26. Grabowska K., Högberg L., Penttinen P., Svensson A., and Ekdahl K. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect. Dis. 6 (2006) 58. http://dx.doi.org/10.1186/1471-2334-6-58 URL http://dx.doi.org/10.1186/1471-2334-6-58
27. Gupta R.K., George R., and Nguyen-Van-Tam J.S. Bacterial pneumonia and pandemic influenza planning. Emerg. Infect. Dis. 14 8 (2008) 1187-1192 Aug
28. Hageman J.C., Uyeki T.M., Francis J.S., Jernigan D.B., Wheeler J.G., Bridges C.B., Barenkamp S.J., Sievert D.M., Srinivasan A., Doherty M.C., McDougal L.K., Killgore G.E., Lopatin U.A., Coffman R., MacDonald J.K., McAllister S.K., Fosheim G.E., Patel J.B., and McDonald L.C. Severe community-acquired pneumonia due to staphylococcus aureus, 2003-04 influenza season. Emerg. Infect. Dis. 12 6 (2006) 894-899 Jun
29. Halloran M.E., Hayden F.G., Yang Y., Longini I.M., and Monto A.S. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am. J. Epidemiol. 165 2 (2007) 212-221. http://dx.doi.org/10.1093/aje/kwj362 URL http://dx.doi.org/10.1093/aje/kwj362. Jan
30. Halloran M.E., Ferguson N.M., Eubank S., Longini I.M., Cummings D.A.T., Lewis B., Xu S., Fraser C., Vullikanti A., Germann T.C., Wagener D., Beckman R., Kadau K., Barrett C., Macken C.A., Burke D.S., and Cooley P. Modeling targeted layered containment of an influenza pandemic in the United States. Proc. Natl. Acad. Sci. U. S. A. 105 12 (2008) 4639-4644. http://dx.doi.org/10.1073/pnas.0706849105 URL http://dx.doi.org/10.1073/pnas.0706849105. Mar
31. Hament J.M., Kimpen J.L., Fleer A., and Wolfs T.F. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS. Immunol. Med. Microbiol. 26 3-4 (1999) 189-195 Dec
32. Handel A., Regoes R.R., and Antia R. The role of compensatory mutations in the emergence of drug resistance. PLoS Comput. Biol. 2 10 (2006) e137. http://dx.doi.org/10.1371/journal.pcbi.0020137 URL http://dx.doi.org/10.1371/journal.pcbi.0020137. Oct
33. Handel A., Longini I.M., and Antia R. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput. Biol. 3 12 (2007) e240. http://dx.doi.org/10.1371/journal.pcbi.0030240 URL http://dx.doi.org/10.1371/journal.pcbi.0030240. Dec
34. Handel A., Longini I.M., and Antia R. What is the best control strategy for multiple infectious disease outbreaks?. Proc. Biol. Sci. 274 1611 (2007) 833-837. http://dx.doi.org/10.1098/rspb.2006.0015 URL http://dx.doi.org/10.1098/rspb.2006.0015. Mar
35. Handel A., Longini I.M., and Antia R. Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details. J. Theor. Biol. 256 1 (2009) 117-125. http://dx.doi.org/10.1016/j.jtbi.2008.09.021 URL http://dx.doi.org/10.1016/j.jtbi.2008.09.021. Jan
36. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersley N., Mills R.G., Ward P., and Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282 13 (1999) 1240-1246 Oct
37. Herlocher M.L., Truscon R., Elias S., Yen H.-L., Roberts N.A., Ohmit S.E., and Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190 9 (2004) 1627-1630. http://dx.doi.org/10.1086/424572 URL http://dx.doi.org/10.1086/424572. Nov
38. Hers J.F., Masurel N., and Mulder J. Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza. Lancet 2 7057 (1958) 1141-1143 Nov
39. Hethcote H.W. The Mathematics of Infectious Diseases. SIAM Review 42 (2000) 599-653
40. Hoare A., Regan D.G., and Wilson D.P. Sampling and sensitivity analyses tools (sasat) for computational modelling. Theor. Biol. Med. Model 5 (2008) 4. http://dx.doi.org/10.1186/1742-4682-5-4 URL http://dx.doi.org/10.1186/1742-4682-5-4
41. Hoti F., Erästö P., Leino T., and Auranen K. Outbreaks of streptococcus pneumoniae carriage in day care cohorts in Finland-implications for elimination of transmission. BMC Infect. Dis. 9 (2009) 102. http://dx.doi.org/10.1186/1471-2334-9-102 URL http://dx.doi.org/10.1186/1471-2334-9-102
42. Jamieson D.J., Honein M.A., Rasmussen S.A., Williams J.L., Swerdlow D.L., Biggerstaff M.S., Lindstrom S., Louie J.K., Christ C.M., Bohm S.R., Fonseca V.P., Ritger K.A., Kuhles D.J., Eggers P., Bruce H., Davidson H.A., Lutterloh E., Harris M.L., Burke C., Cocoros N., Finelli L., MacFarlane K.F., Shu B., Olsen S.J., and Group N.I.A.H.P.W. H1n1 2009 influenza virus infection during pregnancy in the USA. Lancet 374 9688 (2009) 451-458. http://dx.doi.org/10.1016/S0140-6736 URL http://dx.doi.org/10.1016/S0140-6736(09)61304-0. Aug
43. Jennings L.C., Anderson T.P., Beynon K.A., Chua A., Laing R.T.R., Werno A.M., Young S.A., Chambers S.T., and Murdoch D.R. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 63 1 (2008) 42-48. http://dx.doi.org/10.1136/thx.2006.075077 URL http://dx.doi.org/10.1136/thx.2006.075077. Jan
44. Juven T., Mertsola J., Waris M., Leinonen M., Meurman O., Roivainen M., Eskola J., Saikku P., and Ruuskanen O. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr. Infect. Dis. J. 19 4 (2000) 293-298 Apr
45. Kaiser L., Fritz R.S., Straus S.E., Gubareva L., and Hayden F.G. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J. Med. Virol. 64 3 (2001) 262-268 Jul
46. Kaiser L., Keene O.N., Hammond J.M., Elliott M., and Hayden F.G. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med. 160 21 (2000) 3234-3240 Nov
47. Kaiser L., Lew D., Hirschel B., Auckenthaler R., Morabia A., Heald A., Benedict P., Terrier F., Wunderli W., Matter L., Germann D., Voegeli J., and Stalder H. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet 347 9014 (1996) 1507-1510 Jun
48. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., and Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 163 14 (2003) 1667-1672. http://dx.doi.org/10.1001/archinte.163.14.1667 URL http://dx.doi.org/10.1001/archinte.163.14.1667. Jul
49. Kajita E., Okano J.T., Bodine E.N., Layne S.P., and Blower S. Modelling an outbreak of an emerging pathogen. Nat. Rev. Microbiol. 5 9 (2007) 700-709. http://dx.doi.org/10.1038/nrmicro1660 URL http://dx.doi.org/10.1038/nrmicro1660. Sep
50. Klugman K.P., Astley C.M., and Lipsitch M. Time from illness onset to death, 1918 influenza and pneumococcal pneumonia. Emerg. Infect. Dis. 15 2 (2009) 346-347 Feb
51. Klugman K.P., and Madhi S.A. Pneumococcal vaccines and flu preparedness. Science 316 5821 (2007) 49-50. http://dx.doi.org/10.1126/science.316.5821.49c URL http://dx.doi.org/10.1126/science.316.5821.49c. Apr
52. Levy S.B., and Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nature Medicine 10 12 (2004) S122-S129
53. Lim W.S., Macfarlane J.T., Boswell T.C., Harrison T.G., Rose D., Leinonen M., and Saikku P. Study of community acquired pneumonia aetiology (scapa) in adults admitted to hospital: implications for management guidelines. Thorax 56 4 (2001) 296-301 Apr
54. Lipsitch M. The rise and fall of antimicrobial resistance. Trends in Microbiology 9 9 (2001) 438-444
55. Lipsitch M., Cohen T., Murray M., and Levin B.R. Antiviral Resistance and the Control of Pandemic Influenza. PLoS Med. 4 1 (2007) e15. http://dx.doi.org/10.1371/journal.pmed.0040015 URL http://dx.doi.org/10.1371/journal.pmed.0040015. Jan
56. Livermore D.M. Minimising antibiotic resistance. Lancet Infect. Dis. 5 7 (2005) 450-459. http://dx.doi.org/10.1016/S1473-3099 URL http://dx.doi.org/10.1016/S1473-3099(05)70166-3. Jul
57. Lloyd A.L. Destabilization of epidemic models with the inclusion of realistic distributions of infectious periods. Proc. R. Soc. Lond. B 268 (2001) 985-993
58. Longini I.M., and Halloran M.E. Strategy for distribution of influenza vaccine to high-risk groups and children. Am. J. Epidemiol. 161 4 (2005) 303-306. http://dx.doi.org/10.1093/aje/kwi053 URL http://dx.doi.org/10.1093/aje/kwi053. Feb
59. Longini I.M., Nizam A., Xu S., Ungchusak K., Hanshaoworakul W., Cummings D.A.T., and Halloran M.E. Containing pandemic influenza at the source. Science 309 5737 (2005) 1083-1087 Aug
60. Louria D.B., Blumenfeld H.L., Ellis J.T., Kilbourne E.D., and Rogers D.E. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J. Clin. Invest. 38 1 Part 2 (1959) 213-265. http://dx.doi.org/10.1172/JCI103791 URL http://dx.doi.org/10.1172/JCI103791. Jan
61. Madhi S.A., Klugman K.P., and Group V.T. A role for streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10 8 (2004) 811-813 Aug
62. Maeda S., Yamada Y., Nakamura H., and Maeda T. Efficacy of antibiotics against influenza-like illness in an influenza epidemic. Pediatr. Int. 41 3 (1999) 274-276 Jun
63. Marino S., Hogue I.B., Ray C.J., and Kirschner D.E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 254 1 (2008) 178-196. http://dx.doi.org/10.1016/j.jtbi.2008.04.011 URL http://dx.doi.org/10.1016/j.jtbi.2008.04.011. Sep
64. Maxwell E.S., Ward T.G., and Metre T.E.V. The relation of influenza virus and bacteria in the etiology of pneumonia. J. Clin. Invest. 28 2 (1949) 307-318. http://dx.doi.org/10.1172/JCI102073 URL http://dx.doi.org/10.1172/JCI102073. Mar
65. McCullers J.A. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J. Infect. Dis. 190 3 (2004) 519-526. http://dx.doi.org/10.1086/421525 URL http://dx.doi.org/10.1086/421525. Aug
66. McCullers J.A. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19 3 (2006) 571-582. http://dx.doi.org/10.1128/CMR.00058-05 URL http://dx.doi.org/10.1128/CMR.00058-05. Jul
67. McCullers J.A. Planning for an influenza pandemic: Thinking beyond the virus. J. Infect. Dis. 198 7 (2008) 945-947. http://dx.doi.org/10.1086/592165 URL http://dx.doi.org/10.1086/592165. Oct
68. McCullers J.A., and Bartmess K.C. Role of neuraminidase in lethal synergism between influenza virus and streptococcus pneumoniae. J. Infect. Dis. 187 6 (2003) 1000-1009 Mar
69. Memoli M.J., Morens D.M., and Taubenberger J.K. Pandemic and seasonal influenza: therapeutic challenges. Drug Discov. Today. 13 13-14 (2008) 590-595. http://dx.doi.org/10.1016/j.drudis.2008.03.024 URL http://dx.doi.org/10.1016/j.drudis.2008.03.024. Jul
70. Mills C.E., Robins J.M., and Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 432 7019 (2004) 904-906 Dec
71. Moberley S.A., Holden J., Tatham D.P., and Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 1 (2008) CD000422. http://dx.doi.org/10.1002/14651858.CD000422.pub2 URL http://dx.doi.org/10.1002/14651858.CD000422.pub2
72. Moghadas S.M., Bowman C.S., Röst G., and Wu J. Population-wide emergence of antiviral resistance during pandemic influenza. PLoS ONE 3 3 (2008) e1839. http://dx.doi.org/10.1371/journal.pone.0001839 URL http://dx.doi.org/10.1371/journal.pone.0001839
73. Morens D.M., and Fauci A.S. The 1918 influenza pandemic: insights for the 21st century. J. Infect. Dis. 195 7 (2007) 1018-1028. http://dx.doi.org/10.1086/511989 URL http://dx.doi.org/10.1086/511989. Apr
74. Morens D.M., Taubenberger J.K., and Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198 7 (2008) 962-970. http://dx.doi.org/10.1086/591708 URL http://dx.doi.org/10.1086/591708. Apr
75. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 13 (2005) 1363-1373. http://dx.doi.org/10.1056/NEJMra050740 URL http://dx.doi.org/10.1056/NEJMra050740. Sep
76. Nicholson K.G. Textbook of Influenza (1998), Blackwell Science, Ch. Human Influenza 219-264
77. O'Brien K.L., Walters M.I., Sellman J., Quinlisk P., Regnery H., Schwartz B., and Dowell S.F. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin. Infect. Dis. 30 5 (2000) 784-789 May
78. Okamoto S., Kawabata S., Nakagawa I., Okuno Y., Goto T., Sano K., and Hamada S. Influenza a virus-infected hosts boost an invasive type of streptococcus pyogenes infection in mice. J. Virol. 77 7 (2003) 4104-4112 Apr
79. Pourbohloul B., Ahued A., Davoudi B., Meza R., Meyers L.A., Skowronski D.M., Villaseñor I., Galván F., Cravioto P., Earn D.J.D., Dushoff J., Fisman D., Edmunds W.J., Hupert N., Scarpino S.V., Trujillo J., Lutzow M., Morales J., Contreras A., Chávez C., Patrick D.M., and Brunham R.C. Initial human transmission dynamics of the pandemic (h1n1) 2009 virus in North America. Influenza Other Respi Viruses 3 5 (2009) 215-222. http://dx.doi.org/10.1111/j.1750-2659.2009.00100.x URL http://dx.doi.org/10.1111/j.1750-2659.2009.00100.x. Sep
80. Regoes R.R., and Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312 5772 (2006) 389-391 Apr
81. Shann F., Gratten M., Germer S., Linnemann V., Hazlett D., and Payne R. Aetiology of pneumonia in children in Goroka hospital, Papua new guinea. Lancet 2 8402 (1984) 537-541 Sep
82. Sheretz R.J., Reagan D.R., Hampton K.D., Robertson K.L., Streed S.A., Hoen H.M., Thomas R., and Gwaltney J.M. A cloud adult: the Staphylococcus aureus-virus interaction revisited. Ann. Intern. Med. 124 6 (1996) 539-547 Mar
83. Soper G.A. The influenza pneumonia pandemic in the American army camps during September and October. 1918. Science 48 1245 (1918) 451-456. http://dx.doi.org/10.1126/science.48.1245.451 URL http://dx.doi.org/10.1126/science.48.1245.451. Nov
84. Stuart-Harris C.H. Chemotherapy of non-tuberculous pulmonary infections. Br. Med. J. 1 5138 (1959) 1606-1610 Jun
85. Stuart-Harris C.H. Maxwell Finland lecture: the influenza viruses and the human respiratory tract. Rev. Infect. Dis. 1 4 (1979) 592-599
86. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., Singh S., Kinnersley N., Ward P., and Mills R.G. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283 8 (2000) 1016-1024 Feb
87. Viboud C., Tam T., Fleming D., Handel A., Miller M.A., and Simonsen L. Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic. Vaccine 24 44-46 (2006) 6701-6707. http://dx.doi.org/10.1016/j.vaccine.2006.05.067 URL http://dx.doi.org/10.1016/j.vaccine.2006.05.067. Nov
88. Wearing H.J., Rohani P., and Keeling M.J. Appropriate models for the management of infectious diseases. PLoS Med. 2 7 (2005) e174. http://dx.doi.org/10.1371/journal.pmed.0020174 URL http://dx.doi.org/10.1371/journal.pmed.0020174. Jul
89. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., and Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20 2 (2001) 127-133 Feb
90. Woodhead M.A., Macfarlane J.T., McCracken J.S., Rose D.H., and Finch R.G. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1 8534 (1987) 671-674 Mar
91. Wu J.T., Leung G.M., Lipsitch M., Cooper B.S., and Riley S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med. 6 5 (2009) e1000085. http://dx.doi.org/10.1371/journal.pmed.1000085 URL http://dx.doi.org/10.1371/journal.pmed.1000085. May
92. Yang Y., Longini I.M., and Halloran M.E. Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups. J. R. Stat. Soc. Ser. C-Appl. Stat. 55 (2006) 317-330
93. Yang Y., Sugimoto J.D., Halloran M.E., Basta N.E., Chao D.L., Matrajt L., Potter G., Kenah E., and Longini I.M. The transmissibility and control of pandemic influenza a (h1n1) virus. Science (2009). http://dx.doi.org/10.1126/science.1177373 URL http://dx.doi.org/10.1126/science.1177373. Sep
94. Yen H.-L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., and Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49 10 (2005) 4075-4084. http://dx.doi.org/10.1128/AAC.49.10.4075-4084.2005 URL http://dx.doi.org/10.1128/AAC.49.10.4075-4084.2005. Oct
95. Young L.S., LaForce F.M., Head J.J., Feeley J.C., and Bennett J.V. A simultaneous outbreak of meningococcal and influenza infections. N. Engl. J. Med. 287 1 (1972) 5-9 Jul
96. Zhanel G.G., Ennis K., Vercaigne L., Walkty A., Gin A.S., Embil J., Smith H., and Hoban D.J. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62 1 (2002) 13-59